Interestingly, RIPK2 has been demonstrated to be involved in the active growth of CD90 (+) intestinal stromal cells to
suggest an «inflammatory» cross-talk between intestinal stromal cells and the epithelial cells (Owens et al., 2013), and we can observe robust activation of RIPK2 in IBD colon tissue sections immunostained with our proprietary pY474 RIPK2 antibody (Salla et al.,
unpublished observations).